Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Disease-free survival curves of Kif11 with different cancers and the relationships between Kif11 and the von Hippel-Lindau disease tumour suppressor gene (<i>VHL</i>), and proliferating cell nuclear antigen (PCNA) in kidney cancer were further analysed using the GEPIA database.
|
30819726 |
2019 |
Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Glycolysis and antioxidant pathways in kidney cancer are elevated, with frequent mutation of the VHL gene.
|
28408240 |
2017 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases.
|
28701475 |
2017 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
VHL-deficient clear cell renal cell carcinomas (ccRCC), the most common form of kidney cancer, express transcripts derived from the novel human endogenous retrovirus HERV-E (named CT-RCC HERV-E).
|
26862115 |
2016 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, complex indels display strong tissue specificity (such as VHL in kidney cancer samples and GATA3 in breast cancer samples).
|
26657142 |
2016 |
Malignant neoplasm of kidney
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clear cell renal cell carcinoma (ccRCC) is the major subtype of kidney cancer that is characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene in 80-90% of the tumors.
|
25873528 |
2015 |
Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade.
|
24629521 |
2014 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
|
23744542 |
2013 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Renal cancer is resistant to conventional chemotherapy and radiotherapy but increased understanding of the underlying tumour biology is leading to the use and development of targeted therapies, such as tyrosine kinase inhibitors targeting pathways downstream of the von Hippel Lindau tumour suppressor gene.
|
23228867 |
2013 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
|
23223005 |
2013 |
Malignant neoplasm of kidney
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Somatic mutations or loss of expression of tumor suppressor VHL happen in the vast majority of clear cell Renal Cell Carcinoma, and it's causal for kidney cancer development.
|
24260413 |
2013 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
While seven FDA-approved agents that target the VHL pathway have been approved for the treatment of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and gene copy number, will be required to gain a complete understanding of the genetic basis of kidney cancer and of the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with this disease.
|
23038766 |
2012 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review aims to focus on pathways in renal cancer (VHL/HIF, mTOR, c-MYC, c-MET, and immune response) in the respective tumor subtypes, accounting for the effects of targeted therapies and providing the framework to search for relevant predictive biomarkers and propose new trials.
|
21677472 |
2011 |
Malignant neoplasm of kidney
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
|
21602888 |
2011 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) causes the most common form of kidney cancer. pVHL is part of a complex that polyubiquitinates the alpha subunit of the heterodimeric transcription factor HIF.
|
20973793 |
2010 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
VHL is the gene for clear cell kidney cancer.
|
20059341 |
2010 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
The VHL gene is the gene for the hereditary cancer syndrome, von Hippel-Lindau, as well as for the common form of sporadic, noninherited, clear cell kidney cancer.
|
19402075 |
2009 |
Malignant neoplasm of kidney
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Loss of VHL function causes the overexpression of transforming growth factor (TGF)-alpha, leading us to hypothesize that TGF-alpha could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study.
|
19052740 |
2009 |
Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clear-cell renal cell carcinoma (RCC) is the most prevalent form of kidney cancer and is frequently associated with loss of von Hippel-Lindau (VHL) gene function, resulting in the aberrant transcriptional activation of genes that contribute to tumor growth and metastasis, including transforming growth factor-alpha (TGF-alpha), a ligand of the epidermal growth factor receptor (EGFR) tyrosine kinase.
|
18243508 |
2008 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
We investigated whether alcohol is associated with (epi)genetic changes of the von Hippel-Lindau (VHL) gene in renal cell cancer.
|
19064569 |
2008 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
The VHL gene product, pVHL, has multiple functions, but the best documented, and the one most clearly linked to tumor development, relates to its role as the substrate recognition module of a ubiquitin ligase complex that targets hypoxia-inducible factor (HIF) for destruction. pVHL function is often compromised in sporadic kidney cancers, and inhibitors of the HIF-responsive growth factor (vascular endothelial growth factor) are active against this disease. pVHL, by inhibiting atypical protein kinase C and hence JunB, also affects neuronal survival, as do the products of the other genes linked to familial pheochromocytoma or paraganglioma (NF1, RET, SDHB, SDHC, and SDHD).
|
18039096 |
2007 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
Most of what is known about the genetic basis of kidney cancer has been learned from study of the inherited forms of kidney cancer: von Hippel Lindau (VHL gene), hereditary papillary renal carcinoma (c-Met gene), Birt Hogg Dubé (BHD gene), and hereditary leiomyomatosis renal cell cancer (fumarate hydratase gene).
|
17255292 |
2007 |
Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIFalpha for destruction.
|
17220275 |
2007 |
Malignant neoplasm of kidney
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
|
16488999 |
2006 |
Malignant neoplasm of kidney
|
0.700 |
Biomarker
|
disease |
BEFREE |
The von Hippel-Lindau (VHL) gene is the major renal cancer gene in adults.
|
14973063 |
2004 |